Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Inclusion Criteria: * Meet the American College of Rheumatology criteria for the diagnosis of SLE. * The test for plasma CMV DNA viral load is positive. * Age: 18 to 65 years, weight 45-80kg, male or female, gender ratio is not limited. * Apply corticosteroid less than 1.0mg/kg/d. * Written informed consent form. Exclusion Criteria: * Inability to comply with IL-2 treatment regimen; * Other active infections. (hepatitis B or C virus, Epstein-Barr virus, human immunodeficiency virus, Mycobacterium tuberculosis or pneumocystis carinii pneumonia) * Any anti-CMV vaccine within 6 months; * History of intravenous immunoglobulin (IVIG) or leflunomide within 6 months prior to randomization, and those who have undergone plasmapheresis; * Active severe neuropsychiatric manifestations of SLE; * Severe chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases\> 3N)); * Severe complications. (respiratory failure, heart failure or toxic shock) * Complicated with other autoimmune diseases; * Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma); * Pregnancy or lactation in females. * Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information; * Participate in other clinical trial within 3 months.